Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ANAVEX LIFE SCIENCES CORP.

Get SEC filing alerts via email and in your feed for ANAVEX LIFE SCIENCES CORP.

AVXL

ANAVEX LIFE SCIENCES CORP.

About ANAVEX LIFE SCIENCES CORP.

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for central nervous system (CNS) diseases, including Alzheimer's, Parkinson's, and Rett syndrome. Its lead product, ANAVEX®2-73 (blarcamesine), targets sigma-1 receptors to restore cellular homeostasis. With a significant market opportunity, Anavex is advancing multiple clinical trials and leveraging genomic data to enhance treatment precision, addressing critical unmet medical needs in neurodegenerative disorders.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from ANAVEX LIFE SCIENCES CORP.

1
1
ANAVEX LIFE SCIENCES CORP. Anavex Life Sciences Reports Reduced Operating Expenses and Increased Cash Reserves for December 2025 Quarter

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
ANAVEX LIFE SCIENCES CORP. Anavex Life Sciences Reports $46.4 Million Net Loss for Fiscal Year Ending September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
ANAVEX LIFE SCIENCES CORP. Anavex Life Sciences Reports $13.2 Million Net Loss in Q3 Fiscal 2025

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
ANAVEX LIFE SCIENCES CORP. Anavex Life Sciences Reports Q2 Fiscal 2025 Financial Results with Increased Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments